Big drugmakers need new medicines as their blockbusters lose exclusivity. These 143 public biotechs have 260 treatments in Phase 3 or filed with the FDA. Pick an area to see them next to the revenue that area is losing.
$111.8B of 2025 blockbuster sales lose US exclusivity by 2037. 45 public biotechs have 67 treatments in Phase 3 or filed.
See the biotechs →$75.7B of 2025 blockbuster sales lose US exclusivity by 2037. 19 public biotechs have 44 treatments in Phase 3 or filed.
See the biotechs →$112.0B of 2025 blockbuster sales lose US exclusivity by 2037. 22 public biotechs have 31 treatments in Phase 3 or filed.
See the biotechs →$11.7B of 2025 blockbuster sales lose US exclusivity by 2037. 1 public biotech has 2 treatments in Phase 3 or filed.
See the biotechs →$17.1B of 2025 blockbuster sales lose US exclusivity by 2037. 3 public biotechs have 3 treatments in Phase 3 or filed.
See the biotechs →$12.9B of 2025 blockbuster sales lose US exclusivity by 2037. 42 public biotechs have 60 treatments in Phase 3 or filed.
See the biotechs →$19.4B of 2025 blockbuster sales lose US exclusivity by 2037. 29 public biotechs have 53 treatments in Phase 3 or filed.
See the biotechs →This shows where late-stage treatments are being developed, not which companies will be acquired. Other covers eye, kidney, liver, blood, bone, growth and rare metabolic diseases. Pipeline data from Readouts as of 29 September 2026; companies already acquired are left out.